How p53 and lipids influence cancer cell growth and survival
Official title: Regulation of Nuclear Akt by p53, MDM2 and Phosphoinositide Lipids Roles in Oncogenic Transformation and Tumor Progression
Funded at University of Wisconsin-Madison · NIH-10980112 · Data updated 2026-11-12
This study is looking at how certain signals in cancer cells help them grow and survive, focusing on a protein called Akt, to find new ways to treat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $569,441 |
| NIH project number | 1R01CA286492-01A1 |
| Project ID | NIH-10980112 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with breast cancer, particularly those with mutations affecting the p53 protein.
✕Less likely to help
Patients with non-cancerous conditions or those with cancers unrelated to the p53 signaling pathway may not benefit from this research.
What this research studies
This research investigates the role of a specific signaling pathway involving p53 and phosphoinositide lipids in the regulation of cancer cell growth and survival. It focuses on understanding how these components interact to activate a protein called Akt in the nucleus, which is crucial for cell survival and tumor progression. The study aims to uncover the mechanisms behind this activation and how it may differ in cancerous cells compared to normal cells. By exploring these interactions, the research seeks to identify potential targets for new cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating breast cancer by targeting the mechanisms that allow cancer cells to survive and proliferate.
How similar studies have gone: Previous research has shown promising results in targeting the PI3K/Akt signaling pathway in cancer treatment, indicating that this approach may lead to significant advancements.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Anderson, Richard a. — University of Wisconsin-Madison
- Study coordinator: Anderson, Richard a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.